ProteoTech Inc., a private biotechnology company located in the Seattle, WA area (Kirkland, WA), was founded in June 1996 and is focused on targeting amyloid diseases through utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amylodosis.

ProteoTech is developing disease-modifying therapies for amyloid diseases based upon its unique expertise as a pioneer in the growing scientific discovery field of amyloid and proteoglycans.  ProteoTech scientists are representative of just a few hundred scientists in the world that have the background and expertise to develop disease-modifying therapeutics based upon amyloid and/or proteoglycan technologies.

ProteoTech is initially utilizing its expertise to develop therapies for Alzheimer's and Parkinson's and has created and protected a library of small molecule compounds designed specifically to attack what is believed to be one of the major biological sources of these diseases.